GeneDx Holdings Corp. Class A (WGS)

GeneDx delivered strong Q2 2025 results, leading to a raise in full-year guidance, contributing to the stock hitting a 52-week high. GeneDx reported its Q3 2025 earnings, with EPS missing forecasts but revenue surpassing expectations, growing 52% year-over-year, and raised its full-year guidance, but the stock fell. There was significant insider selling by executives. GeneDx announced preliminary 2025 financial results and provided 2026 guidance, projecting revenue growth, but the stock fell after the guidance disappointed investors. GeneDx partnered with Komodo Health to advance rare disease research, announced GenomeDx Prenatal, and appointed Dr. Linda Genen as Chief Medical Officer. GeneDx COO Bryan Dechairo sold shares of Class A Common Stock, and the company announced it would report Q4 2025 financial results on February 23, 2026.

Demand for GeneDx Holdings Corp.'s products and services exhibits some seasonality, with the second half of the year generally considered seasonally stronger for testing volume. The company anticipates that expanded service offerings and the AAP's recommendation of exome and genome sequencing as first-tier tests for children with developmental delays or intellectual disabilities is expected to drive sustained demand starting in 2026.

GeneDx Holdings Corp. is a genomics company specializing in genetic testing services, primarily focusing on pediatric and rare disease diagnostics. The company operates within the Healthcare sector, specifically in the Diagnostics & Research and Healthcare Providers & Services industries. Through its subsidiary, GeneDx, LLC, the company offers exome and genome tests that translate complex genomic data into clinical answers, aiming to unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. Major products and services include whole exome and genome sequencing, with specific test options like XomeDx, XomeDx Plus, XomeDxXpress, GenomeSeqDx, and GenomeXpress. GeneDx also provides a menu of targeted variant testing options and develops an AI-based platform for Next Generation Sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, United States, and primarily operates within the U.S. market. The company is actively expanding its market footprint into new segments, including pediatricians, neonatal intensive care units (NICU), prenatal care, and adult specialists. There are also plans for international expansion. The company benefits from expanding Medicaid coverage, with California recently adding whole genome coverage, bringing the total to 36 states.

In the past year, GeneDx has generally maintained a positive brand reputation, particularly among analysts, with bullish sentiment and numerous "buy" ratings, and has been recognized for its advancements in genomic testing and its strategic positioning in the growing personalized medicine market. However, a former employee filed a lawsuit alleging widespread fraud and illegal tactics by GeneDx to artificially inflate revenue, which could severely damage the company's brand and credibility.

GeneDx Holdings Corp. has 527 institutional owners and shareholders holding a total of 36,434,185 shares, including major institutional owners such as Corvex Management LP, Casdin Capital, LLC, and BlackRock, Inc. Significant insider selling has been observed over the past three months, with executives, including CFO Kevin Feeley and CEO Katherine Stueland, contributing to this net selling.